The treatment of lepra reactions constitutes one of the most serious problems in leprosy. For this reason, the first reports in 1965 of the favourable results obtained with thalidomide aroused considerable interest and led WHO, in 1967, to carry out a trial with the co-operation of four centres. A short-term double-blind trial was designed to study the effect of thalidomide, in comparison with acetylsalicylic acid, in the treatment of acute lepra reactions in male lepromatous patients. Acetylsalicylic acid was used instead of a placebo because of its antipyretic and analgesic activity. Because of the severe adverse reactions that may be caused by thalidomide, mainly the teratogenic effects, only males were included in the trial.The results of this short-term study seem to confirm previous reports of the efficacy of thalidomide and indicate that acetylsalicylic acid also seems to be helpful in the management of certain symptoms of lepra reactions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427977 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Recurrent Type-2 Leprosy Reaction: Keeping the Threshold Low to Suspect Drug-Resistant Mycobacterium leprae.
Int J Dermatol
January 2025
Department of Dermatology, Maulana Azad Medical College, New Delhi, India.
Perforating ENL: A variant of type 2 lepra reaction.
J Clin Tuberc Other Mycobact Dis
February 2025
Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.
Lepra reactions are acute episodic inflammatory reactions that occur during illness due to abrupt changes in the body's immunological response against Mycobacterium leprae. These are of two types, type 1 and type 2. Type 2 reaction is also called Erythema Nodosum Leprosum (ENL).
View Article and Find Full Text PDFBullous type 2 lepra reactions are a rare initial presentation in leprosy that can complicate the disease with vesiculo-bullous lesions. Early recognition and differentiation from other bullous disorders are critical for timely corticosteroid and multidrug therapy initiation to improve patient outcomes.
View Article and Find Full Text PDFExploring the Potential Use of Withania somnifera in Leprosy and Lepra Reactions: A Molecular Docking Approach.
Infect Disord Drug Targets
December 2024
School of Information Technology, SRM University, Sikkim, India.
Introduction: Withania somnifera (Ashwagandha) is a traditional herb that is cur-rently commercially available for treating a variety of illnesses. By evaluating and verifying docking affinity scores, it is possible to explore the potential of the plant for treating leprosy and lepra-reaction as off-label use.
Methods: The sitoindosides were used as ligands along with thalidomide in docking against targets, such as M.
Tofacitinib in Leprosy: A Novel Therapeutic Approach in Chronic Recalcitrant Type II Reactions.
Cureus
November 2024
Dermatology, The Oxford Medical College, Hospital, and Research Centre, Bangalore, IND.
Leprosy is a chronic, infectious, and debilitating disorder that primarily affects the skin and peripheral nerves. The disease course may be complicated by immune-mediated reactions during or after therapy, which may further worsen nerve damage. Type II lepra reaction (T2LR) is a painful inflammatory condition with systemic features, such as fever, tender erythematous nodules, arthritis, neuritis, orchitis, lymphadenitis, and iritis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!